Dna Topoisomerase I Inhibitors Pipeline Insight
DelveInsight’s, “DNA Topoisomerase I Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA Topoisomerase I Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DNA Topoisomerase I Inhibitors Understanding
DNA Topoisomerase I Inhibitors: Overview
DNA topoisomerases regulate the number of topological links between two DNA strands (i.e. change the number of superhelical turns) by catalysing transient single- or double-strand breaks, crossing the strands through one another, then resealing the breaks. Type I topoisomerases are ATP-independent enzymes (except for reverse gyrase), and can be subdivided according to their structure and reaction mechanisms: type IA (Topo IA; bacterial and archaeal topoisomerase I, topoisomerase III and reverse gyrase) and type IB (Topo IB; eukaryotic topoisomerase I and topoisomerase V). These enzymes are primarily responsible for relaxing positively and/or negatively supercoiled DNA, except for reverse gyrase, which can introduce positive supercoils into DNA. This function is vital for the processes of replication, transcription, and recombination.
The companies and academics are working to assess challenges and seek opportunities that could influence DNA Topoisomerase I Inhibitors R&D. The therapies under development are focused on novel approaches for DNA Topoisomerase I Inhibitors.
DNA Topoisomerase I Inhibitors Emerging Drugs Chapters
This segment of the DNA Topoisomerase I Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DNA Topoisomerase I Inhibitors Emerging Drugs
Sacituzumab govitecan: Immunomedics
Sacituzumab govitecan is an antibody–drug conjugate composed of an antitrophoblast cell-surface antigen 2 (Trop-2) IgG1 kappa antibody coupled to SN-38, the active metabolite of irinotecan and a topoisomerase I inhibitor through a proprietary hydrolyzable linker. Currently, it is in Phase III stage of development to treat Solid tumours.
Trastuzumab Deruxtecan: Daiichi Sankyo
Trastuzumab deruxtecan is a HER2 directed antibody drug conjugate (ADC). Designed using Daiichi Sankyo’s proprietary DXd ADC technology, trastuzumab deruxtecan is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. Trastuzumab deruxtecan (5.4 mg/kg) is approved in the U.S. and Japan for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. Trastuzumab deruxtecan (6.4 mg/kg) is also approved in Japan for the treatment of patients with HER2 positive unresectable advanced or recurrent gastric cancer.
Further product details are provided in the report……..
DNA Topoisomerase I Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different DNA Topoisomerase I Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on DNA Topoisomerase I Inhibitors
There are approx. 20+ key companies which are developing the DNA Topoisomerase I Inhibitors. The companies which have their DNA Topoisomerase I Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Immunomedics.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
DNA Topoisomerase I Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
DNA Topoisomerase I Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA Topoisomerase I Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA Topoisomerase I Inhibitors drugs.
DNA Topoisomerase I Inhibitors Report Insights
- DNA Topoisomerase I Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
DNA Topoisomerase I Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing DNA Topoisomerase I Inhibitors drugs?
- How many DNA Topoisomerase I Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of DNA Topoisomerase I Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DNA Topoisomerase I Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for DNA Topoisomerase I Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?